Abstract
Background Multidrug-resistant bacterial pathogens pose a grave threat to global health, with Klebsiella pneumoniae being a particular concern due to its hypervariable extracellular matrix capsule and frequent development of extended-spectrum β-lactamases and other antibiotic defenses. Treating K. pneumoniae-induced infections with antibiotics is becoming increasingly challenging, necessitating the development of new approaches to address this problem. Phages have emerged as a promising alternative to antibiotics due to their high host specificity, abundance in nature, and evolvability. However, their host specificity makes it difficult to target highly diverse bacterial species using phage therapy.
Methods In this study, a K. pneumoniae bacteriophage was characterized using double-agar overlay (DLA), host range testing, and Oxford Nanopore Technologies (ONT) MinION long-read sequencer for whole genome sequencing.
Results The phage was isolated from a hospital sewage drain and showed activity against multi-drug resistant K. pneumoniae, and showed extensive activity against strains from Dhaka, Bangladesh. Sequence analysis confirmed that the phage belonged to the family Siphoviridae, subfamily Unclassified Webervirus.
Conclusion The findings of this study highlight the potential of sewage samples as a rich source of bacteriophages against medically important pathogens. Further studies on the biological characteristics of this K. pneumoniae bacteriophage could yield valuable insights into the development of a potential therapeutic agent for K. pneumoniae specific infections. It is worth noting that although the viruses were only found in sewage from places with increasing reports of K. pneumoniae infections, such as public hospitals, they hold promise for addressing the growing problem of multidrug-resistant bacterial pathogens.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
North South University
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email addresses of authors: Fahad Khan: fahadkhanbd911{at}gmail.com
Mohammad Sami Salman Bhuiyan: sami.salman.bd{at}gmail.com
Syeda Naushin Tabassum: naushintabu{at}gmail.com
Md. Sakib Abrar Hossain: blsakib{at}gmail.com
Aura Rahman: aurarahman4{at}gmail.com
Abdus Sadique: sadique004{at}gmail.com
Abdullah All Jaber: mradnanjaber{at}gmail.com
Fariza Shams: fariza.shams{at}northsouth.edu
Sudhakar Bhandare: sudhakar.bhandare{at}nottingham.ac.uk
Maqsud Hossain: muhammad.maqsud{at}northsouth.edu
Data Availability
The genomic sequence of the novel page has been deposited in GenBank under accession number: OP611406